Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Items 401–500 of 617
Genetic correction strategies for Duchenne muscular dystrophy and their impact on the heart
Johnston, J. R., & McNally, E. M. (2021) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2021.101460 · Cited by 11
Dystrophin and Spectrin, Two Highly Dissimilar Sisters of the Same Family
Delalande, O., Czogalla, A., Hubert, J., Sikorski, A. F., & Rumeur, É. L. (2017) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-319-49674-0_12 · Cited by 12
Therapies in Muscular Dystrophy: Current Concepts and Future Prospects
Urtizberea, J. A. (2000) · European Neurology · doi:10.1159/000008150 · Cited by 11
“Which Gene to Choose? The question may sound trivial, but it is not. In most cases, the defective or missing gene itself is the one to be replaced. Dystrophin in DMD, emerin in X-linked Emery-Dreifuss muscular dystrophy, calpain and sarcoglycans in limb girdle muscular muscular dystrophies and so forth. This points ou…”
BackgroundChapter 11 Adenoviral Gene Delivery
Ragot, T., Opolon, P., & Perricaudet, M. (1997) · Methods in cell biology · doi:10.1016/s0091-679x(08)60381-7 · Cited by 11
Gene therapy review: Duchenne muscular dystrophy case study
Berling, É., Nicolle, R., Laforêt, P., & Ronzitti, G. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.11.005 · Cited by 11
Gorokhova, S., Schessl, J., Zou, Y., Yang, M. L., Heydemann, P. T., Sufit, R. L., Meilleur, K. G., Donkervoort, S. C., Medne, L., Finkel, R. S., et al. (2023) · Med · doi:10.1016/j.medj.2023.02.005 · Cited by 10
Asher, D. R., Dai, D., Klimchak, A. C., Sedita, L. E., Gooch, K. L., & Rodino‐Klapac, L. R. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.002 · Cited by 11
Davies, K. E., & Vogt, J. (2024) · Neuromuscular Disorders · doi:10.1016/j.nmd.2024.04.004 · Cited by 10
“One member of this family (Patient 324) was still ambulant at age 61 years, even though 46% of his DMD gene was missing [ 8 , 13 ].”
InfluentialSelf-citationGene editing and modulation for Duchenne muscular dystrophy
Stephenson, A. A., & Flanigan, K. M. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.029 · Cited by 13
Duchenne Cardiomyopathy Gene Therapy
Shin, J., Bostick, B., Fine, D. M., Yue, Y., & Duan, D. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_9 · Cited by 10
Challenges for gene therapy for muscular dystrophy
Mendell, J. R., & Clark, K. R. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0009-8 · Cited by 14
“The Becker patient reported by England et al. [ 17 ] with a deletion from exon 17 to 48 removed 46% of the coding region from the dystrophin gene and the patient remained ambulatory after age 61 years.”
BackgroundSplice-switching antisense oligonucleotides for pediatric neurological disorders
Zhang, X. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1412964 · Cited by 10
“The dystrophin protein has 24 repeated spectrin-like domains, and truncated dystrophin proteins with fewer spectrin-like repeats were found in patients who showed much milder symptoms (England et al., 1990).”
BackgroundPathological Issues in Dystrophinopathy in the Age of Genetic Therapies
Shahnoor, N., Siebers, E. M., Brown, K. J., & Lawlor, M. W. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012945 · Cited by 10
“As noted above, the existence of mildly symptomatic BMD patients with large deletions in the DMD gene suggested that a shortened dystrophin molecule could still be extremely beneficial to severely symptomatic DMD patients (71).”
BackgroundGene therapy in neuromuscular disorders
Mendonça, R. D. H., & Zanoteli, E. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s135 · Cited by 11
Li, N., & Song, Y. (2022) · Genes · doi:10.3390/genes13112021 · Cited by 12
“The notion of miniaturized dystrophin was based on a Becker muscular dystrophy patient, who remained ambulatory for seven decades despite a deletion of nearly half of the DMD gene [28].”
MethodLee, B. H. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001208 · Cited by 9
Zhou, J., Xin, J., Niu, Y., & Wu, S. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1504-4 · Cited by 9
“Large in-frame deletions in the central rod domain removing more than 35 exons usually led to DMD [8], while deletions of no more than 35 exons likely led to BMD [8, 24, 25].”
BackgroundRecoding Therapies for Genetic Diseases
Keeling, K. M., & Bedwell, D. M. (2009) · Nucleic acids and molecular biology · doi:10.1007/978-0-387-89382-2_6 · Cited by 9
Tselikas, L., Rodrigues, E., Jammal, M., TIEV, K. P., Chayet, C., JOSSELIN-MAHR, L., Gain, M., Tolédano, C., Cabané, J., & Kettaneh, A. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2010.10.353 · Cited by 10
England, J. C., Loughna, S., & Rutland, C. S. (2017) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd4030008 · Cited by 9
Membrane recruitment of nNOSµ in microdystrophin gene transfer to enhance durability
Boehler, J., Ricotti, V., Gonzalez, J. P., Soustek-Kramer, M., Such, L., Brown, K. J., Schneider, J., & Morris, C. A. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.08.009 · Cited by 10
Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy
van Deutekom, J. C., de Kimpe, S. J., & Campion, G. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.04.001 · Cited by 9
Prattis, S. M., Horton, S., Camp, S. D. V., & Kornegay, J. N. (1994) · Journal of Comparative Pathology · doi:10.1016/s0021-9975(08)80278-2 · Cited by 9
Is dystrophin labelling always discontinuous in Becker muscular dystrophy?
Slater, C. R., & Nicholson, L. V. B. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90044-8 · Cited by 9
Self-citationGene transfer therapy for heritable disease: cell and expression targeting
Mitani, K., Clemens, P. R., Ab, M., & Caskey, C. T. (1993) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1993.0019 · Cited by 9
Biau, H. M. (1993) · Nature · doi:10.1038/364673a0 · Cited by 9
Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
Smith, A. G. (2025) · Neurology · doi:10.1212/wnl.0000000000213776 · Cited by 9
Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Tang, A., & Yokota, T. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2447072 · Cited by 10
“When pathogenic variants of muscular dystrophy with large deletions but mild symptoms were observed, research began to investigate the potential of delivering a truncated dystrophin product as a therapy [65].”
Deletion and Duplication Analysis in Males Affected with Duchenne or Becker Muscular Dystrophy
Curtis, A., & Haggerty, D. (2003) · Humana Press eBooks · doi:10.1385/1-59259-138-8:53 · Cited by 8
Gargaun, E., Falcone, S., Solé, G., Durigneux, J., Urtizberea, J. A., Cuisset, J., Benkhelifa‐Ziyyat, S., Julien, L., Boland, A., Sandron, F., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9020219 · Cited by 9
“Current therapeutic dogma is to convert severe phenotype, such as DMD patients into milder BMD-like phenotype patients [47,48].”
BackgroundProspects for gene therapy for inherited cardiomyopathies
Bowles, N. E., Bowles, K. R., & Towbin, J. A. (2000) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(00)00065-5 · Cited by 8
Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium
Bowles, N. E. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00162-4 · Cited by 8
Advances in Duchenne Muscular Dystrophy: Diagnostic Techniques and Dystrophin Domain Insights
Sarvutienė, J., Ramanavičius, A., Ramanavičius, S., & Prentice, U. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083579 · Cited by 10
“These methods include next-generation sequencing [97,98], fundamental [99–102], molecular [103–106], antibody-based immunoas-says [107–111], and enzyme-based immunoassays [112–115], optical/colorimetric [116,117], fluorescent [118–123], and optical detection [124–128] methods are of particular…”
Cardiac Involvement in a Family with Becker Muscular Dystrophy.
Yu, Y., Yamabe, H., FUJITA, H., INDUE, T., Yokota, Y., Nishio, H., Wada, H., Matsuo, M., & Yokoyama, M. (1995) · Internal Medicine · doi:10.2169/internalmedicine.34.919 · Cited by 7
Genome Engineering for Therapeutic Applications
Thakore, P. I., & Gersbach, C. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00003-8 · Cited by 8
Esterhuizen, A. I., Greenberg, L. S., Ballo, R., Goliath, R., & Wilmshurst, J. M. (2016) · South African Medical Journal · doi:10.7196/samj.2016.v106i6.10999 · Cited by 7
Steroid-responsive myalgia in a patient with Becker muscular dystrophy
Higuchi, I., Nakamura, K., Nakagawa, M., Nakamura, N., Usuki, F., Inose, M., & Osame, M. (1993) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(93)90228-q · Cited by 7
Structural Proteins | Dystrophin: A Multifaceted Protein Critical for Muscle Health
Nelson, D. M., & Ervasti, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21355-1 · Cited by 7
Kajhøj, T. Q. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000160 · Cited by 6
“The large size of the Dystrophin gene represents one obstacle to genetic therapy and such treatment approaches generally rely on smaller internally deleted forms based on mutant Dystrophin forms expressed in certain Becker Muscular Dystrophy (BMD) patients exhibiting less severe pathologies [6,7].”
BackgroundPerspectives and Molecular Diagnosis of Duchenne and Becker Muscular Dystrophies
Prior, T. W. (1995) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30308-1 · Cited by 6
Adeno-Associated Virus and AAV Vectors for Gene Delivery
Carter, B., Burstein, H., & PELUSO, R. W. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch6 · Cited by 7
Ultrastructural localization of dystrophin in chicken smooth muscle
Harricane, M.-C., Augier, N., Leger, J. J., Anoal, M., Axelrud-Cavadore, C., & Mornet, D. (1991) · Cell Biology International Reports · doi:10.1016/0309-1651(91)90069-u · Cited by 6
Sakamoto, T., Arima, T., Ishizaki, M., Kawano, R., Koide, T., Uchida, Y., Yamashita, S., Kimura, E., Hirano, T., Maeda, Y., et al. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.02.004 · Cited by 6
Ikeya, K., Saito, K., Hayashi, K., Tanaka, H., Hagiwara, Y., Yoshida, M., Yamauchi, A., Fukuyama, Y., Ishiguro, T., Eguchi, C., et al. (1992) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320430315 · Cited by 6
Treatment and Management of Muscular Dystrophies
Escolar, D. M., O'Carroll, P., & Leshner, R. T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00019-0 · Cited by 9
Redirecting Splicing to Address Dystrophin Mutations: Molecular By-pass Surgery
Wilton, S. D., & Fletcher, S. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_8 · Cited by 7
Molecular Biology of Human Muscle Disease
Dunne, P. W., & Epstein, H. F. (1991) · Nature Biotechnology · doi:10.1038/nbt0191-41 · Cited by 6
Phenotypic Duchenne muscular dystrophy with C-terminal domain
Higuchi, I., Fukunaga, H., Usuki, F., Moritoyo, T., & Osame, M. (1992) · Pediatric Neurology · doi:10.1016/0887-8994(92)90373-7 · Cited by 6
Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance
Sheridan, C. (2016) · Nature Biotechnology · doi:10.1038/nbt0716-675 · Cited by 6
Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain
Foltz, S. J., Qian, R., Yang, J., Elliott, K., Heithoff, B. P., Jasick, H., Smith, J. B., Karumuthil‐Melethil, S., Qiao, C., Liu, Y., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101519 · Cited by 6
Exon skipping in Duchenne Muscle dystrophy due to a silent p.Ser443= mutation in the DMD gene
Joshi, P. R., Jambal, S., Rentsenbat, M., Gläser, D., & Zierz, S. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.04.065 · Cited by 5
Evaluation of Cardiac, Autonomic Functions in Ambulant Patients with Duchenne Muscular Dystrophy
Nayak, A., Apoorva, S. B., Bardhan, M., Rashmi, R., Arunachal, G., Prathyusha, P. V., Nalini, A., Sathyaprabha, T. N., & Udupa, K. (2023) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-023-01473-5 · Cited by 5
“These patients are categorized under in-frame deletion in exons 32–44, 48–51, and 48–53 and surprisingly had normal to near normal concentration of dystrophin [41, 48–50].”
Oliveira, A. S. B., Gabbai, A. A., Schmidt, B., Kiyomoto, B. H., Lima, G. C., Minetti, C., & Bonilla, E. (1992) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1992000400010 · Cited by 5
“(5) One woman, case 10, with three sons with DMD, that could be classified as obligatory carrier did not show any change in the immunostaining with dystrophin.”
BackgroundTargeted Treatments for Inherited Neuromuscular Diseases of Childhood
Fay, A. J., Knox, R. N., Knierbein, E. E. N., & Strober, J. B. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1702940 · Cited by 5
Cooper-Olson, G., Rodino‐Klapac, L. R., & Potter, R. A. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200622 · Cited by 5
“Large deletions in the dystrophin gene that do not disrupt the open reading frame in patients with milder Becker muscular dystrophy result in partially normal muscle structure and function [10].”
BackgroundRegenerative Rehabilitation for Duchenne Muscular Dystrophy
Swiderski, K., Hardee, J. P., & Lynch, G. S. (2022) · Physiology in health and disease · doi:10.1007/978-3-030-95884-8_4 · Cited by 5
The Pathogenesis of Duchenne Muscular Dystrophy
Burton, E. A., & Davies, K. E. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-106-0_12 · Cited by 5
Self-citationRecent Advances in Neuromuscular Disorders in Childhood
Dubowitz, V. (1991) · Pediatrics International · doi:10.1111/j.1442-200x.1991.tb01544.x · Cited by 5
Current Concepts in Dystrophinopathies
Venkataraman, V. (2014) · The Indian Journal of Pediatrics · doi:10.1007/s12098-014-1621-2 · Cited by 5
Reitter, B. F., & Goebel, H. H. (1996) · Seminars in Pediatric Neurology · doi:10.1016/s1071-9091(96)80039-8 · Cited by 5
Bhattacharya, S. K., Johnson, P. L., Li, H.-J., Handa, R. K., & Adamec, T. A. (1997) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815242 · Cited by 5
Duchenne's Muscular Dystrophy: Review and Recent Scientific Findings
Evans, B. K., & Goyne, C. (1991) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199108000-00010 · Cited by 6
Potter, R. A., Griffin, D. A., Heller, K. N., Mendell, J. R., & Rodino‐Klapac, L. R. (2023) · Biology Open · doi:10.1242/bio.059797 · Cited by 4
“…dystrophin contains the functional elements that have been tested in preclinical studies (Gao and Mcnally, 2015) or observed in the clinic (England et al., 1990): the ABD and CRD; spectrin-like repeats R1-3 with membrane-binding properties (Cooper-Olson et al., 2021; Zhao et al., 2016)…”
BackgroundGene therapy in Duchenne muscular dystrophy
Laugel, V. (2025) · Archives de Pédiatrie · doi:10.1016/s0929-693x(25)00254-4 · Cited by 4
Pesco, M. T., Öztürk, G. Z., Bhadola, S., Chrzanowski, S. M., Gushchina, L. V., & D'Ambrosio, E. S. (2026) · Muscles · doi:10.3390/muscles5010021 · Cited by 4
“…dystrophin gene (~14 kb) exceeds the packaging capacity of AAV vectors (~4.7 kb), these therapies use internally deleted constructs containing only the most critical functional domains, similar to the naturally occurring truncated dystrophin seen in the milder Becker muscular dystrophy [31].”
InfluentialOverview of muscular dystrophy, it’s types, symptoms, management and possible treatment
Liaqat, S. T. (2022) · Pure and Applied Biology · doi:10.19045/bspab.2023.120028 · Cited by 4
Neuromuscular Disorders in Pediatric Respiratory Disease
Taylor, J. B., Ingram, D. G., Kupfer, O., & Amin, R. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.02.021 · Cited by 5
Signs of Progress in Gene Therapy for Muscular Dystrophy Also Warrant Caution
Stedman, H. H., & Byrne, B. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.307 · Cited by 4
Atteintes cardiaques au cours de la myopathie de Duchenne
Fayssoil, A., Orlikowski, D., Nardi, O., & Annane, D. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2007.07.010 · Cited by 4
The advances and challenges of Gene Therapy for Duchenne Muscular Dystrophy
Tremblay, J. P. (2017) · Journal of Genetic Medicine and Gene Therapy · doi:10.29328/journal.jgmgt.1001003 · Cited by 6
Bittner, R. E., Shorny, S., Ferlings, R., Sperl, W., Kreß, W., Moller, C. R., Cremer, M., Leger, J. J., & Voït, T. (1995) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)00032-5 · Cited by 4
Duchenne Muscular Dystrophy Animal Models
Egorova, T. V., Galkin, I. I., Ivanova, Y. V., & Polikarpova, A. V. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96738 · Cited by 4
Chapter 31 Immunopathology and molecular genetics of dystrophinopathies
Brown, S., Torelli, S., Jimenez-Mallebrera, C., Muntoni, F., & Sewry, C. A. (2004) · Supplements to Clinical neurophysiology · doi:10.1016/s1567-424x(09)70367-8 · Cited by 4
Toward a gene therapy for duchenne muscular dystrophy
Dunckley, M. G., Piper, T. A., & Dickson, G. (1995) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1410010113 · Cited by 4
Le saut d’exon thérapeutique : un espoir pour les dystrophinopathies
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J., Garcı́a, L., & Danos, O. (2004) · médecine/sciences · doi:10.1051/medsci/200420121163 · Cited by 4
“Cela a conduit au concept de modèles réduits mais encore fonctionnels de la dystrophine: mini-dystrophine, amputée de 46 % de la séquence peptidique [1] et micro-dystrophine, amputée de 60 % [2], très utilisées dans les essais de thérapie génique par transfert de gène.”
BackgroundThe Use Of Skeletal Muscle To Express Genes For The Treatment Of Cancer
Coe, S., Harron, M., Winslet, M. C., & Goldspink, G. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_10 · Cited by 4
Gene Therapy for Duchenne Muscular Dystrophy
van Putten, M., & Aartsma-Rus, A. M. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025029 · Cited by 4
Ghosh, S., Arshi, M. U., Ghosh, S., Jana, A., Jash, M., Khan, J., Ram, H., Mamchaoui, K., & Ghosh, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118777 · Cited by 3
Mechanism of Genome Editing Tools and Their Application on Genetic Inheritance Disorders
Oh, D. H. (2024) · Global Medical Genetics · doi:10.1055/s-0044-1790558 · Cited by 3
“However, BMD, characterized by the presence of partially functional dystrophin that includes the main domains — ABD, CR, and CT — presents with milder symptoms of DMD. 69 70 – 72 By using this knowledge, methods of mitigating symptoms of DMD have been invented.”
Fernandez, C., Halbert, C., de Paula, A. M., Figarella‐Branger, D., Chabrol, B., & Pellissier, J. (2010) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(10)43869-5 · Cited by 4
Strategies to Correct Nonsense Mutations
Benhabiles, H., Jia, J., & Lejeune, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804468-1.00003-8 · Cited by 3
Drug Discovery Approaches for Rare Neuromuscular Diseases
Wynne, G. M., & Russell, A. J. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00257 · Cited by 3
Therapeutic Gene Editing in Muscles and Muscle Stem Cells
Tabebordbar, M., Cheng, J. K. W., & Wagers, A. J. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_10 · Cited by 3
“…that impact this same gene but maintain its open reading frame produce an internally deleted but still partially functional Dystrophin protein that results in a markedly less severe disease known as Becker Muscular Dystrophy (BMD; England et al. 1990; Nakamura et al. 2008; Taglia et al. 2015).”
BackgroundClinical Utility Gene Card for: Becker muscular dystrophy
Coote, D., Davis, M. R., Cabrera‐Serrano, M., Needham, M., Laing, N. G., & Nowak, K. J. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-017-0064-4 · Cited by 3
“However, it is difficult to conclusively predict disease progression from a positive predictive/prenatal test result because of exceptions to the ‘reading frame rule’ and heterogeneity of the BMD phenotype [9, 31, 34].”
Hunting for a cure: The therapeutic potential of gene therapy in Duchenne muscular dystrophy
Hashim, H. Z., Abdullah, S. T. C., Sulaiman, W. A. W., Hoo, F. K., & Basri, H. (2014) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2014.02.002 · Cited by 3
“The patient had only mild disease and was still ambulant at the age of 61 years, despite deletion of almost 50% of the coding information [28].”
BackgroundNovel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents
Wilton, S. D., & Fletcher, S. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s8762 · Cited by 3
Zhao, J.-E., Lochmüller, H., Nalbantoglu, J. N., Allen, C. A., Prescott, S. M., Massie, B., & Karpati, G. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.13-1565 · Cited by 3
A Genetic Intervention Stands a Skip Away from Clinical Tests
Chamberlain, J. S. (2012) · Science · doi:10.1126/science.1233074 · Cited by 3
Functional Enhancement of Skeletal Muscle by Gene Transfer
Gregorevic, P., & Chamberlain, J. S. (2005) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2005.08.011 · Cited by 3
“Large deletions in the dystrophin gene found in some mildly affected patients with the related, although clinically milder Becker muscular dystrophy have spurred efforts to make highly functional ‘‘mini’’ and ‘‘micro’’ versions of dystrophin [28,29,43–47].”
BackgroundMuratore, C. (2010) · Digital Repository Service (Northeastern University) · doi:10.17760/d20000269 · Cited by 3
Human dystrophin gene transfer: genetic correction of dystrophin deficiency
Dickson, G., & Dunckley, M. G. (1993) · Springer eBooks · doi:10.1007/978-94-011-1528-5_11 · Cited by 3
Other innovative therapies in Duchenne muscular dystrophy
Amthor, H. (2025) · Archives de Pédiatrie · doi:10.1016/s0929-693x(25)00255-6 · Cited by 3
Siddika, A., Rousseau, J., Veillette, F., Bouchard, C., Lu, Y., & Tremblay, J. P. (2026) · Cells · doi:10.3390/cells15100852 · Cited by 2
“This outcome is associated https://doi.org/10.3390/cells15100852 with Becker muscular dystrophy (BMD) [38,39], a milder dystrophinopathy compared to Duchenne muscular dystrophy (DMD).”
InfluentialKasden, C. M., Corzo, M. P., Greer, C. D., Singh, T., Reyes, R., Castillo, A., Arany, Z. P., Kozyak, B. W., & Stedman, H. H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.013 · Cited by 2
Advanced Treatments and Emerging Therapies for Dystrophin- Deficient Cardiomyopathies
Camps, J., Pozzo, E., Pulinckx, T., Duelen, R., & Sampaolesi, M. (2017) · InTech eBooks · doi:10.5772/65061 · Cited by 2
“Because of the observation that short isoforms of only 45% of full‐length DYSTROPHIN can lead to a very mild phenotype, mini‐ and microdystrophin were created, leaving behind redundant parts [64, 65].”
BackgroundThe Long Journey from Diagnosis to Therapy
Davies, K. E. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-112019-083518 · Cited by 2
Self-citationMuto, H., Yu, Y., CHAMBERS, J. K., Coghill, L. M., Nakamura, Y., Uchida, K., & Lyons, L. A. (2024) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.17024 · Cited by 3
Duchenne muscular dystrophy, one of the most complicated diseases for gene therapy
Braun, S. (2025) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2024.79 · Cited by 5
Ishikawa, T., Kimoto, H., Seki, A., Shirai, M., Uto, K., Makiyama, T., Kitai, T., Mishima, H., Trujillano, D., Simonet, F., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf135 · Cited by 2
Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy
Aartsma-Rus, A. M., & van Ommen, G. B. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_5 · Cited by 2
“Interestingly, huge in-frame deletions affecting over two-thirds of the central rod domain have been described in mildly affected BMD patients (Dastur et al. 2008; England et al. 1990; Mirabella et al. 1998).”
Background
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.